Franklin Resources’s Fulcrum Therapeutics FULC Stock Holding History

Franklin Resources’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Sell	34,063 -20,603	-38%	-$125K	﹤0.01%	2938
2026 Q1	$419K	Buy	54,666 +10,417	+24%	+$96.6K	﹤0.01%	2534
2025 Q4	$500K	Sell	44,249 -15,773	-26%	-$161K	﹤0.01%	2404
2025 Q3	$552K	Hold	60,022	–	–	﹤0.01%	2389
2025 Q2	$413K	Buy	60,022 +35,201	+142%	+$188K	﹤0.01%	2411
2025 Q1	$71.5K	Hold	24,821	–	–	﹤0.01%	2836
2024 Q4	$117K	Hold	24,821	–	–	﹤0.01%	2742
2024 Q3	$88.6K	Hold	24,821	–	–	﹤0.01%	2756
2024 Q2	$154K	Hold	24,821	–	–	﹤0.01%	2614
2024 Q1	$234K	Hold	24,821	–	–	﹤0.01%	2541
2023 Q4	$168K	Sell	24,821 -3,535	-12%	-$15.7K	﹤0.01%	2386
2023 Q3	$126K	Hold	28,356	–	–	﹤0.01%	2425
2023 Q2	$93.6K	Buy	+28,356	New	+$83.3K	﹤0.01%	2546

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources's FULC Position: Q2 2026 in Review

Franklin Resources reduced its Fulcrum Therapeutics (FULC) stake by 38% in Q2 2026, selling an estimated $125K and leaving 34,063 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

Franklin Resources first reported a position in FULC in Q2 2023 and has held it in 13 quarters since. The position peaked at $552K in Q3 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Franklin Resources held 34,063 shares of Fulcrum Therapeutics worth $125K as of Q2 2026.
Franklin Resources sold 20,603 Fulcrum Therapeutics shares in Q2 2026, an estimated $125K.
Fulcrum Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2938 holding.
Franklin Resources first reported a position in Fulcrum Therapeutics in Q2 2023 and has held it in 13 quarters since.
Franklin Resources's Fulcrum Therapeutics position peaked at $552K in Q3 2025.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.